As of Friday, December 26, Alterity Therapeutics Limited’s ATHE share price has dipped by 6.30%, which has investors questioning if this is right time to buy.

Inspired by his father, Grandview High School student Josue Clara started a nonprofit called Beyond Rare to build awareness ...

While most three-year-olds spend their time attending nursery or playing with friends, Hulus spends his days at clinics and ...

Medcare Royal Specialty Hospital in Al Qusais will provide the newly licensed treatment, called Itvisma, to patients with ...

Discover the most-read SMA stories of 2025, featuring updates on the gene therapy Zolgensma, next-generation treatments, and ...

Now, Musunuru and colleagues are preparing a master clinical protocol to study a CRISPR therapy that's mostly the same as the one they used to treat baby KJ, except they plan to swap out the gene ...

Leuprorelin acetate, a medicine approved in the U.S. for prostate cancer, may slow the progression of SMA type SBMA, ...

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that ...

Treatments are available for dry AMD patients who also have geographic atrophy, but until the FDA's recent authorization of ...

Atrophy Advisor aids in managing GA in AMD by integrating progression and lifespan estimates to guide treatment decisions. GA ...

The next evolution of truFlex fortifies its position as a versatile solution for rehabilitation with new applications in functional strength for the abdomen, arms, calves, glutes and thighs.

The ASX Healthcare sector has finished the week of December 19, 2025 down 1.6% with few signs of a much needed Christmas ...